BETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP) and Abbott (NYSE: ABT) today reported data from a phase 3 clinical efficacy trial in 124 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback